Scolaris Content Display Scolaris Content Display

Nurse‐led titration of angiotensin converting enzyme inhibitors, beta‐adrenergic blocking agents, and angiotensin receptor blockers for people with heart failure with reduced ejection fraction

Abstract

available in

Background

Heart failure is associated with high mortality and hospital readmissions. Beta‐adrenergic blocking agents, angiotensin converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) can improve survival and reduce hospital readmissions and are recommended as first‐line therapy in the treatment of heart failure. Evidence has also shown that there is a dose‐dependent relationship of these medications with patient outcomes. Despite this evidence, primary care physicians are reluctant to up‐titrate these medications. New strategies aimed at facilitating this up‐titration are warranted. Nurse‐led titration (NLT) is one such strategy.

Objectives

To assess the effects of NLT of beta‐adrenergic blocking agents, ACEIs, and ARBs in patients with heart failure with reduced ejection fraction (HFrEF) in terms of safety and patient outcomes.

Search methods

We searched the Cochrane Central Register of Controlled Trials in the Cochrane Library (CENTRAL Issue 11 of 12, 19/12/2014), MEDLINE OVID (1946 to November week 3 2014), and EMBASE Classic and EMBASE OVID (1947 to 2014 week 50). We also searched reference lists of relevant primary studies, systematic reviews, clinical trial registries, and unpublished theses sources. We used no language restrictions.

Selection criteria

Randomised controlled trials (RCTs) comparing NLT of beta‐adrenergic blocking agents, ACEIs, and/or ARBs comparing the optimisation of these medications by a nurse to optimisation by another health professional in patients with HFrEF.

Data collection and analysis

Two review authors (AD & JC) independently assessed studies for eligibility and risk of bias. We contacted primary authors if we required additional information. We examined quality of evidence using the GRADE rating tool for RCTs. We analysed extracted data by risk ratio (RR) with 95% confidence interval (CI) for dichotomous data to measure effect sizes of intervention group compared with usual‐care group. Meta‐analyses used the fixed‐effect Mantel‐Haenszel method. We assessed heterogeneity between studies by Chi2 and I2.

Main results

We included seven studies (1684 participants) in the review. One study enrolled participants from a residential care facility, and the other six studies from primary care and outpatient clinics. All‐cause hospital admission data was available in four studies (556 participants). Participants in the NLT group experienced a lower rate of all‐cause hospital admissions (RR 0.80, 95% CI 0.72 to 0.88, high‐quality evidence) and fewer hospital admissions related to heart failure (RR 0.51, 95% CI 0.36 to 0.72, moderate‐quality evidence) compared to the usual‐care group. Six studies (902 participants) examined all‐cause mortality. All‐cause mortality was also lower in the NLT group (RR 0.66, 95% CI 0.48 to 0.92, moderate‐quality evidence) compared to usual care. Approximately 27 deaths could be avoided for every 1000 people receiving NLT of beta‐adrenergic blocking agents, ACEIs, and ARBs. Only three studies (370 participants) reported outcomes on all‐cause and heart failure‐related event‐free survival. Participants in the NLT group were more likely to remain event free compared to participants in the usual‐care group (RR 0.60, 95% CI 0.46 to 0.77, moderate‐quality evidence). Five studies (966 participants) reported on the number of participants reaching target dose of beta‐adrenergic blocking agents. This was also higher in the NLT group compared to usual care (RR 1.99, 95% CI 1.61 to 2.47, low‐quality evidence). However, there was a substantial degree of heterogeneity in this pooled analysis. We rated the risk of bias in these studies as high mainly due to a lack of clarity regarding incomplete outcome data, lack of reporting on adverse events associated with the intervention, and the inability to blind participants and personnel. Participants in the NLT group reached maximal dose of beta‐adrenergic blocking agents in half the time compared with participants in usual care. Two studies reported on adverse events; one of these studies stated there were no adverse events, and the other study found one adverse event but did not specify the type or severity of the adverse event.

Authors' conclusions

Participants in the NLT group experienced fewer hospital admissions for any cause and an increase in survival and number of participants reaching target dose within a shorter time period. However, the quality of evidence regarding the proportion of participants reaching target dose was low and should be interpreted with caution. We found high‐quality evidence supporting NLT as one strategy that may improve the optimisation of beta‐adrenergic blocking agents resulting in a reduction in hospital admissions. Despite evidence of a dose‐dependent relationship of beta‐adrenergic blocking agents, ACEIs, and ARBs with improving outcomes in patients with HFrEF, the translation of this evidence into clinical practice is poor. NLT is one strategy that facilitates the implementation of this evidence into practice.

PICOs

Population
Intervention
Comparison
Outcome

The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.

See more on using PICO in the Cochrane Handbook.

Plain language summary

Nurse‐led optimisation of medications in heart failure

Review question

To assess the effects of nurse‐led titration (NLT) of beta‐adrenergic blocking agents, angiotensin converting enzyme inhibitors (ACEIs), and angiotensin receptor blockers (ARBs) in patients with heart failure in terms of safety and patient outcomes.

Background

Heart failure has a high rate of hospitalisations and mortality. Large clinical trials have shown that the presence of beta‐adrenergic blocking agents, ACEIs, and ARBs will improve these outcomes. Also, there is a dose response, so the higher the dose of these medications, the greater the improvement in patient outcomes. However, primary care physicians are often reluctant to up‐titrate these medications. New ways of up‐titration of these medications is needed. Optimisation of these medications can be done by nurse practitioners or advanced practice nurses under medical supervision.

Study characteristics

We conducted a review of seven randomised controlled trials (1684 participants) comparing nurse titration of beta‐adrenergic blocking agents, ACEIs, and ARBs with titration of these medications by a primary care physician. The demographic characteristics of participants within each study were similar. There was an equal number of men and women in four of the studies. The mean age of participants ranged from 59 to 81 years of age. The evidence is current up to December 2014.

Key results

The review found that participants undergoing titration of these medications were less likely to experience a hospital admission or to die, and more participants reached the maximum dose compared to those participants having these medications titrated by their primary care physician. Approximately 27 deaths could be avoided for every 1000 patients undergoing titration of these medications by nurses under medical supervision or nurse practitioners. There was very little reported data on the titration of ACEIs and ARBs. Two studies reported on adverse events; one of these studies stated there were no adverse events, and the other study found one adverse event but did not specify the type or severity of the adverse event.

In conclusion, titration of these medications by nurses under medical supervision or nurse practitioners may improve their up‐titration, which may result in an improvement in patient outcomes.

Quality of the evidence

We rated the quality of evidence regarding the proportion of participants that reached optimal dose of these medications as low. This indicates uncertainty as to whether the number of participants reaching optimal dose of beta‐adrenergic blocking agents was different due to NLT or usual care. We found high‐quality evidence that NLT reduced hospitalisations for any cause compared to usual care. This indicates that we are confident that the reduction in all‐cause hospitalisations was due to NLT, and further research is unlikely to change this finding.